Remodeling the
ventricle. Initiating
heart recovery.
A new approach for treating heart
failure patients with reduced ejection fraction.
Contact us
Reshaping the heart.
Reversing the vicious
cycle.
Transcatheter ventricular repair
device for therapeutic remodeling
Contact us

Cardiac Success pioneers an innovative transcatheter procedure to treat HFrEF patients by directly reshaping the ventricle, halting the cycle of deterioration, reducing heart failure symptoms, and initiating heart recovery.

Remodeling the ventricle.
Initiating heart recovery.
A new approach for treating heart failure patients
with reduced ejection fraction.
Contact us
Reshaping the heart.
Reversing the vicious cycle.
Transcatheter ventricular repair device for
therapeutic remodeling
Contact us

Cardiac Success pioneers an innovative transcatheter procedure to treat HFrEF patients by directly reshaping the ventricle, halting the cycle of deterioration, reducing heart failure symptoms, and initiating heart recovery.

*References: 1) AHA Heart Disease and Stroke Statistics Update, Circulation 2017;  2) Vedin et al Ischemic Heart Disease in HeartFailure, 2017;  3) Patel et al Journal ofCardiac Failure Vol. 10 No. 4 2004;  4) Cioffiet al. The European Journal of Heart Failure 7, 2005

Heart remodeling therapy: reversing the vicious cycle

Heart Failure with Reduced Ejection Fraction (HFrEF) affects 1.85 million* symptomatic US patients and many more worldwide, despite guideline-directed therapy. With no effective alternatives, their condition often deteriorates due to the vicious cycle of pathological heart remodeling.

Vsling™

Transcatheter ventricular repair device for HFrEF patients

An innovative transcatheter ventricular remodeling solution for heart failure patients. The Vsling is an atraumatic implant, adjustable in size, and delivered via a low-profile delivery system.

Play Video
Direct treatment of the failed dilated left ventricle for currently untreatable patients
Direct treatment of the failed
dilated left ventricle for
currently untreatable patients

Initiating therapeutic remodeling to reverse the pathological process
Initiating therapeutic
remodeling to reverse the
pathological process

leveraging surgical ventricular remodeling experience while minimizing complications
leveraging surgical ventricular
remodeling experience while
minimizing complications

Intuitive transcatheter procedure with short learning curve
Intuitive transcatheter
procedure with short
learning curve

Direct treatment of the
failed dilated left
ventricle for currently
untreatable patients

Initiating therapeutic remodeling to reverse
the pathological
process

leveraging surgical ventricular remodeling experience while minimizing complications

Intuitive transcatheter procedure with short
learning curve

Clinical experience

The Vsling, an investigational device, is currently undergoing a focused clinical study in Georgia, Israel, and selected European countries. Early findings suggest its promising role in enhancing patients' quality of life and cardiac function.

Clinical
experience

The Vsling, an investigational device, is currently undergoing a focused clinical study in Georgia, Israel, and selected European countries. Early findings suggest its promising role in enhancing patients' quality of life and cardiac function.

Play Video

A Case Study

Highlighting the Significant Potential of Vsling Implantation in Treating Heart Failure Patients.

The patient experienced remarkable improvement, which was sustained at the one-year follow-up, substantially improving his overall well-being and quality of life.

Key Inclusion Criteria

  • Ejection Fraction ≥ 20% and ≤ 40%
  • FMR grade ≤ 2+ (≤ mild)
  • NYHA (New York Heart Association) class II-IVa
  • LV End Diastolic Diameter ≥ 55 mm
  • Cardiomyopathy of ischemic or non-ischemic origins

Key Exclusion Criteria

  • Prior mitral valve replacement
  • Any evidence of structural mitral lesions
  • Severe Aortic stenosis
  • Severe Tricuspid regurgitation
Read More Read Less

A Case Study

A Case Study Highlighting the significant potential of Vsling implantation in treating heart failure patients.

The patient experienced remarkable improvement, which was sustained at the one-year follow-up, substantially improving his overall well-being and quality of life.

Play Video

Key Inclusion Criteria

  • Ejection Fraction ≥ 20% and ≤ 40%
  • FMR grade ≤ 2+ (≤ mild)
  • NYHA (New York Heart Association) class II-IVa
  • LV End Diastolic Diameter ≥ 55 mm
  • Cardiomyopathy of ischemic or non-ischemic origins

Key Exclusion Criteria

  • Prior mitral valve replacement
  • Any evidence of structural mitral lesions
  • Severe Aortic stenosis
  • Severe Tricuspid regurgitation

News

March 23, 2023

Cardiac Success Featured at THT 2023 Conference (Technologies and Heart Failure Therapeutics) in Boston.

The Vsling stood out as a pioneering technology in the heart failure arena. Esteemed speakers, including Dr. Gregg W. Stone, Dr. Horst Sievert, and our CEO, Mr. Boaz Manash, presented our technology, highlighting its potential to revolutionize heartfailure treatment.
read more
January 12, 2022

Cardiac Success Awarded €10M in Grants and Equity Investment from the European Innovation Council

Funds to accelerate the clinical development of the novel “V-sling” system, a transcatheter ventricular repair implant designed to provide a new therapy for heart failure patients.
read more
June 23, 2021

Israeli Medical Device Startup, Cardiac Success Ltd., Closes US $5.2M Series A Financing.

The round was led by 415 CAPITAL, a specialist medical technology venture capital firm who was joined by an unnamed strategic investor and global leader in structural heart interventions…
read more
June 23, 2021

Israeli Medical Device Startup, Cardiac Success Ltd., Closes US $5.2M Series A Financing.

The round was led by 415 CAPITAL, a specialist medical technology venture capital firm who was joined by an unnamed strategic investor and global leader in structural heart interventions…
read more
January 12, 2022

Cardiac Success Awarded €10M in Grants and Equity Investment from the European Innovation Council

Funds to accelerate the clinical development of the novel “V-sling” system, a transcatheter ventricular repair implant designed to provide a new therapy for heart failure patients.
read more
March 23, 2023

Cardiac Success Featured at THT 2023 Conference (Technologies and Heart Failure Therapeutics) in Boston.

The Vsling stood out as a pioneering technology in the heart failure arena. Esteemed speakers, including Dr. Gregg W. Stone, Dr. Horst Sievert, and our CEO, Mr. Boaz Manash, presented our technology, highlighting its potential to revolutionize heartfailure treatment.
read more

Our Team

Boaz Manash

CEO

David Neustadter, PhD

CTO & Founder

Lea Waisman Shaler

COO

Dr. Shimon Eckhouse

Chairman & Co-Founder

Lea Waisman Shaler

COO

Tami Abudi

VP Clinical & Regulatory Affairs

Dr. Shimon Eckhouse

Chairman & Co-Founder

Contact Us

Cardiac Success Ltd. Ofer Bldg. 2, Yokneam
High Tech Park, 2069202 P.O. Box 128, Israel

This project has received funding from
the European Union’s Horizon Europe
under grant agreement No. 190122502

Caution: Investigational device, restricted to investigational use by law.

Cardiac Success Ltd.
Ofer Bldg. 2, Yokneam
High Tech Park, 2069202
P.O. Box 128, Israel

This project has received funding from the European Union’s Horizon Europe under grant agreement No. 190122502

Caution: Investigational device, restricted to investigational use by law.

©2024 Cardiac Success. All rights reserved.

Site by PearlCom

Boaz Manash

MSc, MBA

CEO

Boaz Manash, holding degrees in Mechanical Engineering, Biomedical Engineering, and an MBA in Healthcare Innovations, is an experienced R&D leader in the medical field. He has over 35 patents in interventional cardiology and gastroenterology, with some acquired by notable companies like Medtronic and Boston Scientific. His most recent role was at Edwards Lifesciences, where he led the Sapien M3 transcatheter mitral program, showcasing his expertise in transcatheter structural heart devices.

David Neustadter

PhD

CTO & Founder

David Neustadter has a Ph.D. in Biomedical Engineering from Case Western Reserve University with a focus on muscle mechanics, neural control, and real time Magnetic Resonance Imaging. David worked in MRI physics and regulatory affairs for 5 years at Elscint Ltd. and in MRI systems development and scientific research at GE Medical Systems for 5 years. David has 15 years’ experience as co-founder and CTO of multiple medical startup companies where he was responsible for product definition and development, intellectual property, regulatory submissions, and medical advisory boards.

Lea Waisman Shaler

MSc, MBA

COO

Lea holds a Bachelor’s degree in Mechanical Engineering and a Master’s degree in Biomedical Engineering. With over 15 years of extensive experience in the medical device fields of interventional cardiology and gastroenterology, she specializes in leading conceptual ideas through first-in-human studies and regulatory approval. Her proficiency extends across the entire spectrum of medical device products, encompassing areas such as development, quality, production, regulation, and clinical affairs.

Shimon Eckhouse

PhD

Chairman & Co - Founder

Dr. Eckhouse is an investor and active entrepreneur in the field of medical devices and medical technologies. He is a founder, co-founder and investor in more than 20 companies in medical technology and other high-tech areas. He invented IPL (Intense Pulsed Light) technology, the most popular non-invasive energy-based technology for a broad range of non-invasive medical aesthetic applications. He has authored more than 60 US registered patents and a few hundred international patents as well as more than 50 papers in leading refereed journals and conferences.

Tami Abudi

BSc

VP of Clinical Affairs

Tami Abudi is a clinical and regulatory affairs professional who brings nearly 30 years of experience in developing and running clinical programs within the health care industry. Tami has substantial experience in planning, designing, managing, and publishing clinical studies, including the various steps involved in device development to support worldwide registration, post-market clinical activities, and product launch. Tami holds a Bachelor of Sciences degree from the Life Sciences faculty at Tel Aviv University, Israel.

Skip to content